Atelier 280 - Exploiter le potentiel des NANOBODIES® : d’outils de recherche à agents thérapeutiques
NANOBODIES® sont une marque enregistrée par Ablynx N.V.
Mercredi 25 Septembre 2024 ◘ Wednesday, September 25, 2024 |
||
|
14:00 - 14:30 |
Reception of participants | |
| 14:30 - 14:45 | Welcome and presentation by the organizers | |
| Keynote Lecture |
Route planner to generate best possible NANOBODIES® as a tool in research applications, diagnostics or therapeutics |
|
| 14:45 - 15:30 | Serge Muyldermans (Vrije Universiteit Brussel, Brussels, Belgium) | |
| SESSION I | NANOBODIES® IN STRUCTURAL BIOLOGY | |
| 15:30 - 16:15 |
Engineering NANOBODIES® for structural biology, molecular pharmacology & drug discovery |
|
| Jan Steyeart (Vrije Universiteit Brussel, Brussels, Belgium) | ||
| 16:15 - 17:00 | Use of NANOBODY®-binding Fab (NabFab) for high-resolution cryo-EM studies of membrane proteins | |
| Kaspar Locher (ETH, Zurich, Swizerland) | ||
| 17:00 - 17:30 | Coffee break | |
| 17:30 - 18:15 |
NANOBODIES® as crystallization chaperones |
|
| Philippe Leone (LISM, Marseille, France) | ||
| 18:15 - 19:00 |
Cryo-electron microscopy to engineer NANOBODIES® against variable bacterial surface structures |
|
| Guillaume Dumenil (Institut Pasteur, Paris, France) | ||
| 19:00 - 19:45 | POSTER SESSION | |
| 19:45 | Dinner | |
Jeudi 26 Septembre 2024 ◘ Thursday, September 26, 2024 |
||
| 06:30 - 08:30 | Breakfast | |
| SESSION II | NANOBODIES® IN CELL BIOLOGY AND IMAGING | |
| 08:30 - 09:15 | Nano- and Chromobodies: versatile probes to modulate, visualize and quantify proteins in vitro and in vivo | |
| Ulrich Rothbauer (University of Tübingen, Tübingen, Germany) | ||
| 09:15 - 10:00 |
Opportunities and challenges of NANOBODIES® in targeted protein degradation |
|
| Laura Dassama (University of Stanford, Stanford, USA) | ||
| 10:00 - 10:30 | Coffee break | |
| 10:30 - 11:15 |
Strategies for imaging multiple targets using engineered NANOBODIES® with erasable signals |
|
| Felipe Opazo (University of Gottingen, Gottingen, Germany) | ||
| 11:15 - 12:00 |
Engineering NANOBODIES® for intracellular applications |
|
| John Dingus (University of Harvard, Boston, USA) | ||
| 12:00 - 12:45 | Round table: Immune, non-immunzed or synthetic libraries to generate specific NANOBODIES®? | |
| 12:45 - 14:45 | Lunch and POSTER SESSION | |
| SESSION III | NANOBODIES® AS DIAGNOSTIC TOOLS | |
| 14:45 - 15:30 |
NANOBODY®-based fluorescent contrast agents for rapid and specific intra-operative tumor visualization |
|
| Sophie Hernot (Vrije Universiteit Brussel, Brussels, Belgium) | ||
| 15:30 - 16:15 |
Non-invasive imaging of the immune response using NANOBODIES® modified for use in positron emission tomography |
|
| Ploegh Hidde (Boston Children’s Hospital, Boston, USA) | ||
| 16:15 - 17:00 | Coffee Break | |
| 17:00 - 17:45 | TBD | |
| Pierre Lafaye (Institut Pasteur, Paris, France) | ||
| 17:45 - 18:30 | Improvement of histopathological diagnostics using non-destructive 3D histopathology and NANOBODY® technology | |
| René Hägerling (Institute of Medical and Human Genetics, Charité - Universitätsmedizin Berlin, Berlin, Germany BIH Center for Regenerative Therapies, Berlin Institute of Health, Berlin, Germany) | ||
| 18:30 - 19:15 | Round table: Contribution of Next-Generation Sequencing (NGS) for the selection of antigen-specific NANOBODIES® | |
| 19:15 - 20:15 | Cocktail | |
| 20:15 | Dinner | |
Vendredi 27 Septembre 2024 ◘ Friday, September 27, 2024 |
||
| 07:00 - 09:00 | Breakfast | |
| SESSION IV | NANOBODIES® AS THERAPEUTICS | |
| 09:00 - 9:45 |
Targeting multiple myeloma with NANOBODY®-based heavy chain antibodies, bispecific cell engangers, chimeric antigen receptors and adeno-associated viral vectors |
|
| Friedrich Koch-Nolte (University Medical Center Hamburg, Hamburg, Germany) | ||
| 9:45 - 10:30 |
NANOBODIES® modulating human and viral chemokine receptor function |
|
| Martine Smit (Amsterdam Institute for Molecular and Life Sciences, Vrije Universiteit Amsterdam, Amsterdam, Netherlands) | ||
| 10:30 - 11:00 | Coffee Break | |
| 11:00 - 11:45 | Single domain antibodies as novel therapeutic agents for brain diseases | |
| Philippe Rondard (Institute of functional genomics, Montpellier, France) | ||
| 11:45 - 12:30 | Advances in Gamma Delta T Cell-Targeting Bispecifics for The Treatment of Cancer | |
| Pauline van Helden (LAVA Therapeutics, Utrecht, Netherland) | ||
| 12:30 - 14:00 | Lunch | |
| 14:00 | Departure | |